Revision as of 17:56, 30 December 2024 editBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,805 edits created drug stubTag: nowiki added | Revision as of 18:01, 30 December 2024 edit undoBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,805 editsm added synonymNext edit → | ||
Line 86: | Line 86: | ||
| NIAID_ChemDB = | | NIAID_ChemDB = | ||
| PDB_ligand = | | PDB_ligand = | ||
| synonyms = | | synonyms = 2'-Deoxythioguanosine | ||
<!-- Chemical and physical data --> | <!-- Chemical and physical data --> |
Revision as of 18:01, 30 December 2024
Pharmaceutical compound
Clinical data | |
---|---|
Other names | 2'-Deoxythioguanosine |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C10H13N5O3S |
Molar mass | 283.31 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Ateganosine is a telomerase inhibitor and apoptosis inducer currently under investigation for the treatment of various cancers, including non-small cell lung cancer (NSCLC).
References
- Eglenen-Polat B, Kowash RR, Huang HC, Siteni S, Zhu M, Chen K, et al. (January 2024). "A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer". Nature Communications. 15 (1): 672. doi:10.1038/s41467-024-44861-8. PMC 10803750. PMID 38253555.
- "Ateganosine". PatSnap.
This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |